CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Recipharm AB is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Recipharm AB
Ioffice Vasagatan 10
Phone: +46 86025200p:+46 86025200 STOCKHOLM, 111 20  Sweden Fax: +46 8818703f:+46 8818703

This is a Subsidiary, click here for the Parent Company

Business Summary
Recipharm AB (publ) is a Sweden-based pharmaceutical company, operating as a Contract Development and Manufacturing Organization (CDMO). The Company's acivities are devided into four business segments: Advanced Delivery Systems, which develops and manufactures inhalation products and devices including integrated drug solutions, medical check valves and injection devices. Steriles, which manufactures sterile products, including the use of lyophilisation and blow-fillseal (BFS) technologies. Solids & Others, which manufactures non-sterile products, including tablets, capsules, semi-solids, liquids and powders but excluding inhalation products and Development & Licensing, which provides pharmaceutical development services, and manages Recipharm’s patents, technologies, and drug product rights, as well as the development and manufacturing of drug substance (Active Pharmaceutical Ingredient, API). The Company operates worldwide.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/202012/31/2020Yes----

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board RichardRidinger 64
Chief Executive Officer MarcFunk 62
Chief Operating Officer LucBurgard
Chief Human Resource Officer ChristopheLamacq
Head of Business Unit Oral Solid Dosages GregorKawaletz

Business Names
Business Name
Aesica
Aesica BC Limited
Aesica Formulation Development Limited
53 additional Business Names available in full report.

General Information
Number of Employees: 8,666 (As of 12/31/2020)
Outstanding Shares: 101,485,683 (As of 12/31/2020)
Shareholders: 9,450
Stock Exchange: STO
Fax Number: +46 8818703


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, February 1, 2024